Quick Answer
Immunome Inc. reported R&D Expense of $177.29 million for fiscal year 2025.
Immunome Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $177.29M | +36.9% |
| 2024 | $129.54M | +461.1% |
| 2023 | $23.09M | -0.8% |
| 2022 | $23.27M | +64.9% |
| 2021 | $14.11M | +88.5% |
| 2020 | $7.49M | -15.2% |
| 2019 | $8.82M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $49.19M | +32.2% | +21.6% |
| June 30, 2025 | $40.45M | +39.1% | +9.7% |
| March 31, 2025 | $36.87M | +139.9% | -0.9% |
| September 30, 2024 | $37.20M | +873.1% | +27.9% |
| June 30, 2024 | $29.08M | +408.8% | +89.2% |
| March 31, 2024 | $15.37M | +292.8% | +302.0% |
| September 30, 2023 | $3.82M | -26.8% | -33.1% |
| June 30, 2023 | $5.72M | -0.0% | +46.1% |
- Immunome Inc. showed an increase of +36.9% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, Immunome Inc.’s r&d expense has grown by 1909.4% (from $8.82 million to $177.29 million).
- The most recent figure is from Immunome Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: